ACRUX LIMITED — Regulatory Filings 2022

Nov 2, 2022

==> picture [82 x 79] intentionally omitted <==

ASX Release

3 November 2022

Receipt of R&D Tax Incentive Rebate – Overseas Finding

Melbourne, Australia; Acrux Limited (ASX:ACR) is pleased to announce receipt of $92,704 from the Australian Tax Office relating to a subsidiary company’s Overseas Finding claim.

This is the fourth and final balance which has been received under the Company’s R&D Tax Incentive program for the 2021/2022 financial year and brings the total amount claimed and received to $3,731,741.

The R&D Tax Incentive is an Australian Government program which provides valued industry support to companies conducting eligible research and development.

Authorised for release by the Board of Acrux Limited.

For more information, please contact: Michael Kotsanis Acrux Limited CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Drawing on 25 years of experience and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au